QCG
NTLA icon

Quadrant Capital Group’s Intellia Therapeutics NTLA Stock Holding History

Quadrant Capital Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,052
Closed -$13.5K – 2120
2026
Q1 		$13.5K Sell
1,052
-99
-9% -$1.26K ﹤0.01% 2120
2025
Q4 		$10.3K Hold
1,151
– – ﹤0.01% 2198
2025
Q3 		$19.9K Buy
+1,151
New +$14.2K ﹤0.01% 1956
2025
Q2 		– Sell
-2,520
Closed -$17.9K – 2166
2025
Q1 		$17.9K Buy
2,520
+2,058
+445% +$20.8K ﹤0.01% 2065
2024
Q4 		$5.39K Buy
462
+419
+974% +$6.54K ﹤0.01% 2282
2024
Q3 		$884 Sell
43
-570
-93% -$13.1K ﹤0.01% 2609
2024
Q2 		$13.7K Buy
613
+231
+60% +$5.5K ﹤0.01% 2007
2024
Q1 		$10.5K Sell
382
-94
-20% -$2.61K ﹤0.01% 2085
2023
Q4 		$14.5K Buy
476
+436
+1,090% +$12.5K ﹤0.01% 1933
2023
Q3 		$1.26K Buy
40
+9
+29% +$349 ﹤0.01% 2458
2023
Q2 		$1.26K Sell
31
-166
-84% -$6.73K ﹤0.01% 2479
2023
Q1 		$7.34K Buy
197
+179
+994% +$7.02K ﹤0.01% 2142
2022
Q4 		$628 Sell
18
-148
-89% -$7.04K ﹤0.01% 2596
2022
Q3 		$9K Hold
166
– – ﹤0.01% 1931
2022
Q2 		$9K Buy
166
+130
+361% +$6.6K ﹤0.01% 1728
2022
Q1 		$3K Sell
36
-25
-41% -$2.12K ﹤0.01% 2072
2021
Q4 		$7K Sell
61
-79
-56% -$9.9K ﹤0.01% 1772
2021
Q3 		$19K Buy
140
+80
+133% +$12.1K ﹤0.01% 1265
2021
Q2 		$10K Buy
60
+28
+88% +$2.18K ﹤0.01% 1575
2021
Q1 		$3K Buy
+32
New +$2.15K ﹤0.01% 1967
2020
Q2 		– Sell
-15
Closed – – 2344
2020
Q1 		$0 Buy
+15
New +$202 ﹤0.01% 2216

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Quadrant Capital Group's NTLA Position: Q2 2026 in Review

Quadrant Capital Group sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 1,052 shares — an estimated $13.5K sold.

Quadrant Capital Group first reported a position in NTLA in Q1 2020 and held it in 21 quarters. The position peaked at $19.9K in Q3 2025. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Quadrant Capital Group reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 1,052 Intellia Therapeutics shares in Q2 2026, an estimated $13.5K.
  • Quadrant Capital Group first reported a position in Intellia Therapeutics in Q1 2020 and held it in 21 quarters.
  • Quadrant Capital Group's Intellia Therapeutics position peaked at $19.9K in Q3 2025.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.